Semaglutide Type 1 Diabetes: Biomarkers & Personalized Care

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes and weight management, has emerged as a subject of clinical interest in type 1 diabetes research. Recent studies suggest GLP-1 agonists may provide adjunctive glycemic control and potential cardioprotective benefits in select T1D populations, though regulatory approval and clinical guidelines remain limited.

For individuals with type 1 diabetes exploring treatment optimization, understanding the interplay between biomarkers, genetic predispositions, and medication response can support more informed conversations with endocrinologists. PlexusDx focuses on precision-wellness approaches that combine compounded medication access with genetic insights to help contextualize individual treatment pathways.

GLP-1 Agonists in Type 1 Diabetes: Current Clinical Evidence

Type 1 diabetes fundamentally differs from type 2 in pathophysiology—autoimmune destruction of pancreatic beta cells rather than insulin resistance. Early clinical evidence suggests GLP-1 agonists may reduce insulin requirements, improve glycemic variability, and provide weight-neutral or weight-loss benefits in T1D, though outcomes vary significantly among individuals.

Published trials including SGLT-2 inhibitor and GLP-1 combinations in T1D show mixed but promising results. Most major endocrinology societies position GLP-1 therapy as adjunctive rather than primary T1D treatment, emphasizing that insulin therapy remains the cornerstone of T1D management and that GLP-1 use requires careful provider monitoring.

Biomarker Assessment: A Framework for T1D Treatment Personalization

Personalized T1D care increasingly incorporates biomarker assessment—measuring glucose variability, C-peptide levels, autoimmune markers, and cardiometabolic risk indicators to guide adjunctive therapy decisions. These biomarkers provide context for individual treatment response and help providers estimate whether a GLP-1 agonist aligns with specific patient goals such as weight management, glycemic stability, or cardiovascular protection.

Biomarker Category	Clinical Relevance to GLP-1 Consideration
Residual Beta Cell Function (C-peptide)	Higher residual function may suggest better tolerance and glycemic response to GLP-1 adjunctive therapy.
Glycemic Variability (SD, CV)	Elevated variability may indicate benefit from GLP-1's effect on glucagon suppression and meal-related glucose excursions.
Cardiometabolic Risk (lipids, BP, hsCRP)	Elevated markers may support GLP-1 consideration for cardiovascular and metabolic protection benefits.
Autoimmune Markers (GAD, IA-2, ZnT8)	Persistent high-titer autoimmunity may influence long-term prognosis and adjunctive therapy planning.

Genetic Predispositions in GLP-1 Pathway Response

Emerging research indicates that genetic variation in GLP-1 receptor function and metabolic pathways may influence how individuals respond to GLP-1 agonists. Key variants in genes such as GLP1R, GIPR, and FTO can affect receptor sensitivity, glucose metabolism, and weight-response potential—though genetic testing does not predict exact medication outcomes.

Understanding individual genetic predispositions in peptide pathways may help providers contextualize treatment expectations and tailor dosing or adjunctive strategies. This precision-wellness approach shifts away from generic dosing toward conversation-informed, individually relevant therapy planning.

Safety Considerations and Provider-Guided Decision Making

GLP-1 agonists in type 1 diabetes require careful provider oversight. Off-label use of semaglutide in T1D remains outside FDA-approved indications, and thyroid-related adverse events, pancreatitis risk, and diabetic ketoacidosis (DKA) considerations must be thoroughly evaluated before initiation. Patients with personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe pancreatitis are generally contraindicated.

Any consideration of semaglutide or other GLP-1 agonists in type 1 diabetes should involve direct discussion with an endocrinologist or qualified diabetes specialist. This conversation should address individual glycemic targets, cardiovascular goals, medication interactions, monitoring requirements, and realistic outcome expectations before treatment begins.

How PlexusDx Supports a More Personalized Approach

PlexusDx offers compounded semaglutide injection ($149/mo) and oral semaglutide ($209+/month) through licensed 503A compounding pharmacies, providing cost-accessible options for patients exploring GLP-1 therapy under provider guidance. These compounded formulations are not FDA-approved branded medications and should only be used as part of a comprehensive, provider-supervised treatment plan.

The Precision Peptide Genetic Test ($99 as an add-on, $298 standalone) may help provide context by revealing individual predispositions in key peptide pathway genes including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These predispositions can support a more informed conversation with your provider about potential treatment response patterns—though genetic testing does not predict exact medication outcomes or guarantee efficacy.

If you and your provider are evaluating semaglutide or other GLP-1 agonists for type 1 diabetes management, genetic and biomarker context may help tailor that discussion to your individual profile. PlexusDx is designed to bridge precision testing, compounded medication access, and provider-centered decision making—supporting a personalized care pathway aligned with your specific goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.